Arcus closes Gilead amendment; receives $725M option fees for 3 programs

Arcus Biosciences, Inc.

Closed amendment to Option, License and Collaboration Agreement with Gilead on Dec 21, 2021.
Gilead acquires rights to anti-TIGIT (domvanalimab/AB308), adenosine antagonist (etrumadenant), CD73 (quemliclustat).
Gilead to pay $725 million in option fees, expected early Q1 2022.

item 8.01

Arcus Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-21-005305

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.